Drugs for Anogenital Venereal Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 51)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Imiquimod |
Approved, Investigational |
Phase 4 |
|
99011-02-6 |
57469 |
Synonyms:
1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
Aldara
Aldara®|R837|S-26308|Zyclara®
Imiquimod
Imiquimod acetate
|
Imiquimodum
R 837
R-837
S-26308
ZARTRA
Zyclara
|
|
2 |
|
Cantharidin |
Approved, Investigational |
Phase 4 |
|
56-25-7 |
2545 |
Synonyms:
1,2-Dimethyl-3,6-epoxyperhydrophthalic anhydride
CANTHARIDIN
Cantharidine
Cantharone
|
exo-1,2-cis-Dimethyl-3,6-epoxyhexahydrophthalic anhydride
Kantharidin
NSC-61805
|
|
3 |
|
Cianidanol |
Approved, Withdrawn |
Phase 4 |
|
154-23-4 |
9064 |
Synonyms:
(-)-Epicatechin
(+)-(2R,3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3',4'-Tetrahydroxyflavan-3-ol
(+)-(2R:3S)-5,7,3’,4’-Tetrahydroxyflavan-3-ol
(+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-3’,4’,5,7-Tetrahydroxy-2,3-trans-flavan-3-ol
(+)-Catechin
(+)-Catechin hydrate
(+)-Catechol
(+)-Cianidanol
(+)-Cyanidan-3-ol
(+)-Cyanidanol
(+)-Cyanidanol-3
(+/-)-catechin
(+/-)-catechin hydrate
(2R,3S)-(+)-Catechin
(2R,3S)-Catechin
(2R-trans)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol
3,3',4',5,7-Flavanpentol
Acid, catechinic
Acid, catechuic
Biocatechin
CATECHIN
Catechinate
|
Catechinic acid
Catechuate
Catechuic acid
Catergen
Cianidanol
Cianidanolum
Cianidol
Cyanidanol
Cyanidanol 3
Cyanidanol-3
Cyanidol
D-(+)-Catechin
D-Catechin
D-Catechol
Dexcyanidanol
Epicatechin
KB 53
KB-53
trans-(+)-3,3',4',5,7-Flavanpentol
trans-(+)-3,3’,4’,5,7-Flavanpentol
trans3,3,4,5,7 Pentahydroxyflavane
YK-85 light yellow powder 85
Zyma
|
|
4 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
5 |
|
Epicatechin |
Investigational |
Phase 4 |
|
490-46-0 |
58571364 72276 |
Synonyms:
(-)-Epicatechin
(-)-Epicatechol
(+)-Catechin
(+)-Cyanidanol
(+)-Cyanidanol-3
(2R,3R)-(-)-Epicatechin
3,3',4',5,7-Flavanpentol
3,3',4',5,7-Pentahydroxyflavane
Acid, catechinic
Acid, catechuic
alpha-Catechin
Catechin
Catechinic acid
Catechuic acid
Catergen
Cianidanol
Cyanidanol 3
|
Cyanidanol-3
EC
Epicatechin
Epi-catechin
Epicatechin-(2a->7,4a->8)-epicatechin 3-galactoside
Epicatechin-(2α->7,4α->8)-epicatechin 3-galactoside
Epicatechol
Epigallocatechin
KB 53
KB-53
L(-)-Epicatechin
L-Acacatechin
L-Epicatechin
L-Epicatechol
NSC-81161
Zyma
|
|
6 |
|
Tea |
|
Phase 4 |
|
|
|
7 |
|
Adjuvants, Immunologic |
|
Phase 4 |
|
|
|
8 |
|
Podophyllin |
Approved |
Phase 3 |
|
9000-55-9 |
|
Synonyms:
Podofillina
Podophyllum (resin)
|
|
|
9 |
|
Petrolatum |
Approved, Investigational |
Phase 3 |
|
8009-03-8 |
|
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum
Petrolatum base
Petrolatum, white
Petrolatum,amber
|
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
|
|
10 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
11 |
|
Picropodophyllin |
Approved, Investigational |
Phase 3 |
|
518-28-5, 477-47-4 |
10607 72435 |
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
12 |
|
Insulin, Globin Zinc |
|
Phase 3 |
|
|
|
13 |
|
Insulin |
|
Phase 3 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
14 |
|
Keratolytic Agents |
|
Phase 3 |
|
|
|
15 |
|
Dermatologic Agents |
|
Phase 3 |
|
|
|
16 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
17 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
18 |
|
interferons |
|
Phase 3 |
|
|
|
19 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
20 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
21 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
22 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
23 |
|
Interferon-gamma |
|
Phase 3 |
|
|
|
24 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
25 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
26 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
27 |
|
Vaccines |
|
Phase 3 |
|
|
|
28 |
|
Nitric Oxide |
Approved |
Phase 2 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(NO)(.)
[NO]
EDRF
Endogenous nitrate vasodilator
Endothelium-derived nitric oxide
Endothelium-derived relaxing factor
HYDROXYAMINE
INOmax
INOmax®|nitric oxide|nitrogen monoxide
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, nitrogen
Monoxido de nitrogeno
Monóxido de nitrógeno
Monoxyde d'azote
Nitrate vasodilator, endogenous
NITRIC OXIDE
Nitric oxide, endothelium derived
Nitric oxide, endothelium-derived
Nitrogen monooxide
|
Nitrogen monoxide
Nitrogen oxide
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
NO(.)
OHM-11771
Oxide, nitric
Oxido de nitrogeno(II)
óxido de nitrógeno(II)
Oxido nitrico
óxido nítrico
Oxyde azotique
Oxyde nitrique
Stickstoff(II)-oxid
Stickstoffmonoxid
Vasodilator, endogenous nitrate
|
|
29 |
|
Sodium citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
30 |
|
Coal tar |
Approved |
Phase 2 |
|
8007-45-2 |
|
Synonyms:
|
31 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
32 |
|
Ranpirnase |
Investigational |
Phase 1, Phase 2 |
|
196488-72-9 |
|
Synonyms:
|
33 |
|
Ammonium trichloro(dioxoethylene-O,O'-)tellurate |
|
Phase 1, Phase 2 |
|
|
|
34 |
|
Radiation-Protective Agents |
|
Phase 1, Phase 2 |
|
|
|
35 |
|
Reverse Transcriptase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
36 |
|
Protective Agents |
|
Phase 1, Phase 2 |
|
|
|
37 |
|
Pharmaceutical Solutions |
|
Phase 1, Phase 2 |
|
|
|
38 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
39 |
|
Anticoagulants |
|
Phase 2 |
|
|
|
40 |
|
Citrate |
|
Phase 2 |
|
|
|
41 |
|
Chelating Agents |
|
Phase 2 |
|
|
|
42 |
|
Calcium |
Nutraceutical |
Phase 2 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
43 |
|
Cidofovir |
Approved |
Phase 1 |
|
113852-37-2 |
60613 |
Synonyms:
({[(S)-1-(4-AMINO-2-OXO-1,2-DIHYDROPYRIMIDIN-1-YL)-3-HYDROXYPROPAN-2-YL]OXY}METHYL)PHOSPHONIC ACID
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonate
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-HPMPC
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonate
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-AMINO-2-OXO-1(2H)-PYRIMIDINYL)-1-(HYDROXYMETHYL)ETHOXY]METHYL]PHOSPHONIC ACID
1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine
1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
|
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
CDV
Cidofovir
Cidofovir anhydrous
Cidofovir sodium
Cidofovir, (+-)-isomer
Cidofovir, (R)-isomer
Cidofovir, sodium salt
CIDOFOVIRUM
GS-0504
HPMPC
Vistide
|
|
44 |
|
Aminolevulinic acid |
Approved |
|
|
106-60-5 |
137 |
Synonyms:
5 Aminolaevulinate
5 Aminolevulinate
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
|
ácido 5-aminolevulínico
Aladerm
Aminolevulinate
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
dALA
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
Hydrochloride, aminolevulinic acid
Kerastick
Levulan
δ-ALA
Δ-aminolevulinate
δ-aminolevulinic acid
|
|
45 |
|
Formaldehyde |
Approved, Vet_approved |
|
|
50-00-0 |
712 |
Synonyms:
Aldeide formica
Fannoform
Formaldehído
Formaldehyd
Formaldehyde
Formaldehyde solution
FORMALIN
Formalina
Formaline
Formalith
Formic aldehyde
|
Formol
Hyperband
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
|
|
46 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
47 |
|
Photosensitizing Agents |
|
|
|
|
|
48 |
|
Contraceptive Agents |
|
|
|
|
|
49 |
|
Interleukin-4 |
|
|
|
|
|
50 |
|
Anti-Infective Agents, Local |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 99)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts |
Completed |
NCT00189293 |
Phase 4 |
Imiquimod |
2 |
Alternate Dosing Schedules Study for HPV Vaccine |
Completed |
NCT00862810 |
Phase 4 |
|
3 |
An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage |
Completed |
NCT01082302 |
Phase 4 |
Polyphenon E (Veregen) 15% ointment |
4 |
Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts |
Completed |
NCT03625960 |
Phase 4 |
Cantharidin;Trichloroacetic Acid |
5 |
A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts |
Terminated |
NCT01468636 |
Phase 4 |
Oral Zinc;Placebo |
6 |
The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study |
Unknown status |
NCT03853785 |
Phase 3 |
Topical Podophyllin |
7 |
Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place |
Unknown status |
NCT03296397 |
Phase 3 |
|
8 |
Betaglucin 0.2% Gel Versus Imiquimod Cream 5% in the Treatment of Anogenital Warts in 102 Individuals Older Than 18 Years. |
Unknown status |
NCT03901690 |
Phase 3 |
Betaglucin soluble gel 0.2%;Imiquimod 5% cream |
9 |
Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients |
Unknown status |
NCT03153566 |
Phase 3 |
|
10 |
A Randomized, Double-Blind, Three-Arm Parallel-Group, Placebo-Controlled Phase 3 Trial to Investigate the Clinical Efficacy and Safety of Polyphenon E in the Treatment of External Genital Warts |
Completed |
NCT00449982 |
Phase 3 |
Polyphenon E Ointment 10%, Polyphenon E Ointment 15% |
11 |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts |
Completed |
NCT00674739 |
Phase 3 |
Imiquimod;3.75% imiquimod cream;placebo cream |
12 |
A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts |
Completed |
NCT00735462 |
Phase 3 |
2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream |
13 |
A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women |
Completed |
NCT00092521 |
Phase 3 |
|
14 |
Phase III Study of the Treatment of Genital Warts by Low Dose Cyclophosphamide |
Completed |
NCT00999986 |
Phase 3 |
cyclophosphamide |
15 |
Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease |
Completed |
NCT00517309 |
Phase 3 |
|
16 |
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine |
Completed |
NCT00501137 |
Phase 3 |
|
17 |
A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women |
Completed |
NCT00543543 |
Phase 3 |
|
18 |
A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine |
Completed |
NCT00092495 |
Phase 3 |
|
19 |
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women |
Completed |
NCT01651949 |
Phase 3 |
|
20 |
A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ |
Completed |
NCT01047345 |
Phase 3 |
|
21 |
An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) |
Completed |
NCT03158220 |
Phase 3 |
|
22 |
Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) |
Completed |
NCT00092482 |
Phase 3 |
|
23 |
An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men |
Completed |
NCT00090285 |
Phase 3 |
|
24 |
A Phase III Open-label Safety and Immunogenicity Study of GARDASILâ„¢9 Administered to 9- to 26-Year-Old Females and Males in Vietnam |
Completed |
NCT03546842 |
Phase 3 |
|
25 |
Open Controlled Randomized Study of the Efficacy and Safety of Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (Phase III) |
Completed |
NCT05156541 |
Phase 3 |
Interferon gamma human recombinant (IFN-G) |
26 |
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts. |
Completed |
NCT03532776 |
Phase 3 |
Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel |
27 |
A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years |
Completed |
NCT04425291 |
Phase 3 |
|
28 |
Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents. |
Completed |
NCT01111344 |
Phase 3 |
|
29 |
A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years |
Completed |
NCT05372016 |
Phase 3 |
|
30 |
Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts |
Recruiting |
NCT02750202 |
Phase 3 |
|
31 |
A Phase 3 Open-Label Immunogenicity and Safety Study of 2-Dose Regimens of V503, a 9-Valent Human Papillomavirus (HPV) Vaccine in Chinese Males 9 Through 14 Years Old and 3-Dose Regimen of V503 in Chinese Males 9 Through 19 Years Old |
Recruiting |
NCT05314023 |
Phase 3 |
|
32 |
Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial |
Recruiting |
NCT04895020 |
Phase 3 |
|
33 |
A Multicenter,Randomized,Blind and Positive-Controlled Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years |
Recruiting |
NCT04422366 |
Phase 3 |
|
34 |
Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial |
Recruiting |
NCT05027776 |
Phase 3 |
|
35 |
A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) |
Active, not recruiting |
NCT00092534 |
Phase 3 |
|
36 |
A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck & Co., Inc.) in Healthy Females 18-26 Years of Age |
Active, not recruiting |
NCT04782895 |
Phase 3 |
|
37 |
Immunogenicity Non-inferiority Immuno-bridging Study of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine (E.Coli) in Healthy Population Aged 9-17 Years Old vs Aged 18-26 Years Old |
Active, not recruiting |
NCT05056402 |
Phase 3 |
|
38 |
A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years |
Active, not recruiting |
NCT04537156 |
Phase 3 |
|
39 |
A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years. |
Active, not recruiting |
NCT05580341 |
Phase 3 |
|
40 |
A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age. |
Active, not recruiting |
NCT04635423 |
Phase 3 |
|
41 |
A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years |
Not yet recruiting |
NCT05584332 |
Phase 3 |
|
42 |
Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma |
Terminated |
NCT01639638 |
Phase 2, Phase 3 |
PROAPOPTOTIC PEPTIDE CIGB 300 |
43 |
A Phase II, Multicenter, Randomized, Double Blind, Vehicle Controlled Study Evaluating the Efficacy and Tolerability of AS101 15% Gel for External Genital Warts. |
Unknown status |
NCT01943630 |
Phase 2 |
15% AS101 gel;Vehicle |
44 |
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts |
Completed |
NCT02462187 |
Phase 2 |
NVN1000 8% Gel;NVN1000 16%;Vehicle;NVN1000 24% |
45 |
Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV |
Completed |
NCT02535104 |
Phase 1, Phase 2 |
Ranpirnase;Vehicle |
46 |
A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs) |
Completed |
NCT02482428 |
Phase 2 |
Investigational Treatment;Aldara |
47 |
A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts |
Completed |
NCT03981822 |
Phase 2 |
|
48 |
A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs) |
Completed |
NCT01796821 |
Phase 2 |
Vehicle gel;SR-T100 gel with 1.0 % SM;SR-T100 gel with 2.3% SM |
49 |
A Phase I/II, Open Labeled, Uncontrolled, Single Center Study of Topical AS101 for External Genital Warts |
Completed |
NCT01555112 |
Phase 1, Phase 2 |
Topical AS101 |
50 |
A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group Study to Explore the Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts |
Completed |
NCT02849262 |
Phase 2 |
Omiganan (CLS001) topical gel;Vehicle topical gel |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
imiquimod
Interferon Alfa-2b
Interferon Alfa-n3
|
podophyllin
PODOPHYLLIN PWDR
|
|